News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Eli Lilly has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).
A new treatment for esophageal squamous cell carcinoma (ESCC) from Shanghai-based Henlius Biotech has been approved by the National Medical Products Administration (NMPA).
MC2 Therapeutics has acquired the exclusive licensing rights for Regranion’s RGRN-305, a new treatment for hidradenitis suppurativa (HS).